AETNA Covers Xiaflex for Peyronie’s Disease as Medically Necessary

Latest News – Aetna has approved coverage for Xiaflex for Peyronie’s disease. As per their policy:

Aetna considers Xiaflex (collagenase Clostridium histolyticum) for the treatment of Peyronie’s disease medically necessary when it is administered under the Risk Evaluation and Mitigation Strategy (REMS) program.  (Note: A treatment course for Peyronie’s disease consists of a maximum of 4 treatment cycles (each separated by 6 weeks).  Each treatment cycle consists of 2 Xiaflex injection procedures (in which Xiaflex is injected directly into the collagen-containing structure of the penis) and 1 penile modeling procedure).

The actual cost to the patient varies by plan and may include copays; coinsurance and deductibles. Charity help is available for patients needing Xiaflex for Peyronie’s disease.

 

Last modified on April 5, 2014